KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Research & Development: 2009-2024

Historic Research & Development for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $747.2 million.

  • Biomarin Pharmaceutical's Research & Development rose 121.46% to $409.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.0 million, marking a year-over-year increase of 15.78%. This contributed to the annual value of $747.2 million for FY2024, which is 0.06% up from last year.
  • Biomarin Pharmaceutical's Research & Development amounted to $747.2 million in FY2024, which was up 0.06% from $746.8 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Research & Development registered a high of $747.2 million during FY2024, and its lowest value of $628.1 million during FY2020.
  • In the last 3 years, Biomarin Pharmaceutical's Research & Development had a median value of $746.8 million in 2023 and averaged $714.5 million.
  • In the last 5 years, Biomarin Pharmaceutical's Research & Development decreased by 12.15% in 2020 and then increased by 14.96% in 2023.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Research & Development stood at $628.1 million in 2020, then increased by 0.11% to $628.8 million in 2021, then increased by 3.31% to $649.6 million in 2022, then increased by 14.96% to $746.8 million in 2023, then grew by 0.06% to $747.2 million in 2024.